Dave: so, next week we may not hear about definitive contracts or sales for Lympro. That might actually happen and I hope it does. However, there are 2 other things we could hear about. In conjunction with the conference we could hear about a build out of the relationship with ICON or some other entity getting involved. That could produce an actual cash payment. We could also hear about this diagnostic acquisition GC has mentioned.

Either way, AMBS has a few things on the docket that cost money. Diagnostic new acquisition, Eltoprazine trial, and ESS rights etc. This company has way too many smart people involved pushing these activities if they didn't think they were getting significant cash from somewhere and soon.